should glp-1 agonists be open access The Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs A clinician's perspective π GLP-1
Description
Robert Kushner: Well, the BMI classifications, the cut points you mentioned, have actually now been removed by the FDA for semaglutide and the other drug called tirzepatide, the two major drugs on the market
The investment in manufacturing capacity signals confidence in future demand and the company's ability to capture a significant share of the generic market

Canadian family physician Medecin de famille canadien, 67(11), 842

As it consumes mucus, it stimulates the goblet cells in your intestinal lining to produce more

Ma Y, Lee E, Yoshikawa H, Noda T, Miyamoto J, Kimura I, et al
